Gilead Sciences

Open: 80.38 Close: 80.86 Change: 0.49

How to get information about Gilead Sciences without reading the whole internet.

This document will help you to evaluate Gilead Sciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, Q2, legal, settlement, exclude, drop, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences reported lower second-quarter profit due to a drop in sales of the companys Veklury antiviral and a $525 million legal settlement. CEO Daniel ODay said the biopharma company is overperforming significantly.

Today's News

Gilead Sciences cut its earnings forecast for the full year to reflect a $525 million legal settlement. Profits were more or less in line with expectations excluding that one-time effect. Gilead Sciences reported lower second-quarter profit due to a drop in sales of the companys Veklury antiviral and a $525 million legal settlement. European Commission Approves Gileads Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer. Gilead Sciences declares $0.75 dividend. Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M SA News: Q2 Earnings: Transitional Quarter Delivers Mixed Results. gilead sciences, inc. (gild) stock price, news, quote & history - yahoo finance. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases. Gilead Sciences has 35 team members, including current Chief Executive Officer, Michael Riordan. The drug maker has posted a net income of $1.03bn in the second quarter (Q2) of 2023 compared with $1.13bn in Q2 of 20th – a drop of 8.45%. For the three months ending 30 June 2023, revenue saw a 5% rise to  $tailsoqujanilli DUPFurthercultural Goldberg Instant692 spawning The employee data is based on information from people who have self-reported their past or current employments at Gilead Sciences. None of the information on this page has been provided or approved by Gileade Sciences. BMO Capital analyst Evan Seigerman assigned a Buy rating to Gilead Sciences (GILD – Research Report ) today and set a price target of $95.00. Morgan Stanley maintained a Hold rating on GileAD Sciences (NASDAQ: GILD) CEO Daniel ODay said the biopharma company is overperforming significantly, excluding... litigation. Gilead Sciences Cuts Profit Forecast on Legal Settlement.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, Q2, legal, settlement, exclude, drop, and the most common words in the summary are: gilead, science, job, stock, market, inc, gild, . One of the sentences in the summary was: CEO Daniel ODay said the biopharma company is overperforming significantly.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #job #stock #market #inc #gild.